Dr. Satkirin Khalsa
Family Medicine (Family Medicine Physician)
At a glance
- Medical school
- University of New Mexico School of Medicine (2004)
- Years since graduation
- 22
- In the NPI registry since
- 2005
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2004Medical school: University of New Mexico School of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Family Medicine Physician primary
NM license MD2007-0257
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Steven D Hsi, MD, PC (7 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Industry-funded research
Named as a principal investigator on 25 industry-funded studies in 2025, from 11 companies. The companies reported $2,489,856 in research payments for these studies, mostly to the institutions running them.
- A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis
ModernaTX, Inc. · Active, not recruiting · NCT06592794 - A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age
Seqirus USA Inc · Completed · NCT06087640 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
AbbVie Inc. · Active, not recruiting · NCT06417775 - A Study Evaluating the Safety and Efficacy of Intra-articular Injections of TPX-100 in Subjects With Mild to Moderate Patello-Femoral Osteoarthritis Involving Both Knees
American Regent · Completed · NCT01925261 - PUREST
C. R. Bard, Inc. & Subsidiaries - Dose-Ranging Study of the Efficacy and Safety of TAK-101 for Prevention of Gluten-Specific T Cell Activation in Participants With Celiac Disease on a Gluten-Free Diet
Takeda Pharmaceuticals U.S.A., Inc. · Completed · NCT04530123 - M23-714 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
AbbVie Inc. - A phase third,randomised,double blind,placebo controlled,eventdriven study to evaluate the effect of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on the risk of incident heart failure…
AstraZeneca Pharmaceuticals LP - A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age
ModernaTX, Inc. · Completed · NCT05575492 - A phase 4, multicenter, open-label, single-arm study to investigate the efficacy of lebrikizumab in adult and adolescent participants with atopic dermatitis with limited body surface area involvement and high itch bur…
Eli Lilly and Company
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.